Phase 2Completed

Vitamin K2 Intervention in Patients With Vitamin K Antagonists (SAFEK)

Study of the Effect of Food Vitamin K2 Intake in Association With a Fermented Dairy Product on Patients Treated With Vitamin K Antagonist (VKA)

Sponsor
Danisco (Industry)
Enrollment
50 enrolled
Conditions
Thrombosis
Interventions
Vitamin K2
Ages
adults, older adults
Registry
NCT01533441

Full record on ClinicalTrials.gov

From the registry

The objective of the SAFE K study is to demonstrate that in patients treated with the antagonists of vitamin K (VKA), a daily intake of vitamin K2 (75 micrograms/day) as naturally produced by the ferments used in fermented dairy products, does not upset the balance of anticoagulant treatment.Fifty-two patients will be chosen to receive either verum or placebo for four months after a 4-month run-in period.In addition, the study evaluates if regular consumption of vitamin K2 reduce the need of changing the dose of anticoagulation treatment and improve the markers of bone mineralisation.

Primary outcomes

  • INR

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started